BioNTech Cuts 1,860 Jobs and Unleashes $1B Buyback as Oncology Pipeline Prepares for ASCO Spotlight
23.05.2026 - 09:41:37 | boerse-global.de
BioNTech is entering the busiest week of its oncology calendar with a starkly mixed message: the company is slashing over a tenth of its workforce and closing multiple production sites, while simultaneously gearing up to launch six more Phase 3 trials by year-end. The contrasting signals reflect a biotech in full transition from pandemic-era vaccine maker to next-generation cancer specialist, and the market is watching closely.
The Mainz-based group announced the closure of facilities in Idar-Oberstein, Marburg, Tübingen and Singapore, affecting approximately 1,860 positions. The restructuring is expected to generate annual savings of up to €500 million from 2029 onwards. At the same time, the board authorised a share buyback programme of up to $1 billion over twelve months — a move that underscores management’s confidence in the company’s balance sheet. BioNTech finished the first quarter with €16.8 billion in cash and equivalents.
That financial buffer is being tested by a deteriorating income statement. First-quarter revenue slumped to €138 million as Covid vaccine sales continued their decline, while the net loss widened to €622 million. Research spending surged to €651.6 million, driven largely by oncology and antibody-drug conjugate programmes. The company reiterated its full-year revenue guidance of €2.3 billion to €2.6 billion.
All eyes this week are on the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, running from 29 May to 2 June. BioNTech lands two oral presentations that could define the near-term direction of the stock. The first covers pumitamig, a bispecific immunomodulator combining PD-L1 inhibition with VEGF-A neutralisation. Interim data from the Phase 2/3 ROSETTA Lung-02 trial showed encouraging antitumour activity in first-line non-small cell lung cancer across various PD-L1 expression levels, when combined with chemotherapy. This marks the third consistent dataset for the asset, following earlier signals in small cell lung cancer and triple-negative breast cancer. A head-to-head Phase 3 study comparing pumitamig plus chemo against pembrolizumab plus chemo is already underway.
Should investors sell immediately? Or is it worth buying BioNTech?
The second ASCO presentation focuses on gotistobart, a CTLA-4 antibody designed to selectively deplete regulatory T cells. In the Phase 2 PRESERVE-004 study, gotistobart combined with pembrolizumab delivered durable responses and clinically meaningful overall survival improvements in heavily pre-treated patients with platinum-resistant ovarian cancer. The safety profile remained manageable, building the case for a chemotherapy-free treatment option in a difficult-to-treat population.
The oncology push does not end with ASCO. BioNTech currently runs more than 25 Phase 2 and Phase 3 studies, including 13 pivotal trials. The company plans to launch six additional Phase 3 trials in 2026, bringing the total to 15 late-stage programmes. Seven late-stage data readouts are expected by year-end — a pace that keeps the pipeline in the spotlight but also heightens execution risk.
That risk is front and centre for analysts. Bernstein initiated coverage on the stock with a “Market Perform” rating and a $96 price target, citing a nuanced view: BioNTech’s strong balance sheet and broad pipeline justify a better rating than a comparable company that Bernstein rates “Underperform,” but approval risk remains elevated. J.P. Morgan recently reaffirmed its “Hold” stance. Yet the broader consensus among 17 analysts stands at “Buy,” with an average price target of $125.45 — implying roughly 38% upside from current levels.
BioNTech at a turning point? This analysis reveals what investors need to know now.
The stock itself reflects the tension. At around €79.50, BioNTech shares trade nearly 10% above their 52-week low of €72.50 but remain 8% below the 200-day moving average. On a monthly basis the stock has lost more than 15%. The relative strength index sits at 50.6, offering no clear directional signal. The market is effectively pricing in a binary outcome: either the ASCO data validate the pipeline and close the gap to analyst targets, or the cautious Bernstein view prevails, keeping the shares tethered near their lows.
Ad
BioNTech Stock: New Analysis - 23 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
